Search research articles
Contact Us
Filters
Showing results (21-30 of 49) with videos related to
Page
of 5
Sort By:
The Australian & New Zealand Journal of Obstetrics & Gynaecology
|
July 29, 2024
The impact of the COVID-19 public health response on service demand and patient perceptions in a tertiary Australian gynaecology oncology unit
Nooraishah Yasin, Michael Yu, Kristen Jones, et al.
The Australian & New Zealand Journal of Obstetrics & Gynaecology
|
August 1, 2025
Before the Burn: Predicting Endometrial Ablation Failure
Anne Woolfield, Jessica Phillips, Ian Hughes, et al.
Molecular Cancer Therapeutics
|
December 15, 2021
Resistance Profile and Structural Modeling of Next-Generation ROS1 Tyrosine Kinase Inhibitors
Clare Keddy, Pushkar Shinde, Kristen Jones, et al.
Nanotechnology
|
September 16, 2011
Role of dopant concentration, crystal phase and particle size on microbial inactivation of Cu-doped TiO2 nanoparticles
Manoranjan Sahu, Bing Wu, Liying Zhu, et al.
Chemmedchem
|
August 20, 2019
Second-Generation Inhibitors of the Mitochondrial Permeability Transition Pore with Improved Plasma Stability
Justina Šileikytė, Jordan Devereaux, Jelle de Jong, et al.
Neurosurgery
|
February 14, 2025
The Role of Minimally Invasive Surgery in Spinal Trauma: A Review of Techniques, Outcomes, and Limitations
Mounica R Paturu, Joshua Woo, Brett Rocos, et al.
NPJ Precision Oncology
|
August 8, 2024
TKI type switching overcomes ROS1 L2086F in ROS1 fusion-positive cancers
Rajat Thawani, Matteo Repetto, Clare Keddy, et al.
Biorxiv : the Preprint Server for Biology
|
January 31, 2024
TKI Type Switching Overcomes ROS1 L2086F in ROS1 Fusion-Positive Cancers
Rajat Thawani, Matteo Repetto, Clare Keddy, et al.
NPJ Precision Oncology
|
August 28, 2024
Author Correction: TKI type switching overcomes ROS1 L2086F in ROS1 fusion-positive cancers
Rajat Thawani, Matteo Repetto, Clare Keddy, et al.
EMBO Molecular Medicine
|
August 17, 2023
Discovery of oncogenic ROS1 missense mutations with sensitivity to tyrosine kinase inhibitors
Sudarshan R Iyer, Kevin Nusser, Kristen Jones, et al.
Page
of 5
Search research articles
Search
Showing results (21-30 of 49) with videos related to
Sort By:
Page
of 5
The Australian & New Zealand Journal of Obstetrics & Gynaecology
|
July 29, 2024
The impact of the COVID-19 public health response on service demand and patient perceptions in a tertiary Australian gynaecology oncology unit
Nooraishah Yasin, Michael Yu, Kristen Jones, et al.
The Australian & New Zealand Journal of Obstetrics & Gynaecology
|
August 1, 2025
Before the Burn: Predicting Endometrial Ablation Failure
Anne Woolfield, Jessica Phillips, Ian Hughes, et al.
Molecular Cancer Therapeutics
|
December 15, 2021
Resistance Profile and Structural Modeling of Next-Generation ROS1 Tyrosine Kinase Inhibitors
Clare Keddy, Pushkar Shinde, Kristen Jones, et al.
Nanotechnology
|
September 16, 2011
Role of dopant concentration, crystal phase and particle size on microbial inactivation of Cu-doped TiO2 nanoparticles
Manoranjan Sahu, Bing Wu, Liying Zhu, et al.
Chemmedchem
|
August 20, 2019
Second-Generation Inhibitors of the Mitochondrial Permeability Transition Pore with Improved Plasma Stability
Justina Šileikytė, Jordan Devereaux, Jelle de Jong, et al.
Neurosurgery
|
February 14, 2025
The Role of Minimally Invasive Surgery in Spinal Trauma: A Review of Techniques, Outcomes, and Limitations
Mounica R Paturu, Joshua Woo, Brett Rocos, et al.
NPJ Precision Oncology
|
August 8, 2024
TKI type switching overcomes ROS1 L2086F in ROS1 fusion-positive cancers
Rajat Thawani, Matteo Repetto, Clare Keddy, et al.
Biorxiv : the Preprint Server for Biology
|
January 31, 2024
TKI Type Switching Overcomes ROS1 L2086F in ROS1 Fusion-Positive Cancers
Rajat Thawani, Matteo Repetto, Clare Keddy, et al.
NPJ Precision Oncology
|
August 28, 2024
Author Correction: TKI type switching overcomes ROS1 L2086F in ROS1 fusion-positive cancers
Rajat Thawani, Matteo Repetto, Clare Keddy, et al.
EMBO Molecular Medicine
|
August 17, 2023
Discovery of oncogenic ROS1 missense mutations with sensitivity to tyrosine kinase inhibitors
Sudarshan R Iyer, Kevin Nusser, Kristen Jones, et al.
Page
of 5